Clinical Trial Update: Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

View source ↗

Summary

An observational study evaluating Kesimpta (ofatumumab) in Greek patients with relapsing multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis (RMS) | Status: RECRUITING